Mintz, Levin, Cohn, Ferris, Glovsky and Popeo advised Amring Pharmaceuticals Inc. on the transaction, and Wilson Sonsini Goodrich & Rosati advised Visant Medical. Amring Pharmaceuticals Inc....
Amring Pharmaceuticals’ Acquisition of Visant Medical
Soleno Therapeutics’ $120 Million Common Stock Offering and Private Placement
Wilson Sonsini Goodrich & Rosati and Cooley advised Soleno Therapeutics on the deal. Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno”) announced the pricing of the underwritten public offering of...
L Catterton’s $680 Million Acquisition of Thorne HealthTech
Kirkland & Ellis LLP is representing L Catterton, and Wilson Sonsini Goodrich & Rosati is representing Thorne HealthTech, Inc. in the transaction. Thorne HealthTech, Inc. (“Thorne”)...
SetPoint Medical’s $80 Million Preferred Stock Financing
Wilson Sonsini Goodrich & Rosati advised SetPoint Medical on the deal. SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced an...
Enable Injections’ $215 Million Series C Financing
Wilson Sonsini Goodrich & Rosati advised Enable Injections on the deal. Enable Injections, Inc., a company developing and manufacturing the enFuse platform of investigational wearable drug...
Codex DNA’s Collaboration and License Agreement with Pfizer
Wilson Sonsini Goodrich & Rosati advised Codex DNA on the deal. Codex DNA, a leader in the development of automated solutions for on-demand synthesis of genes...
Thorne HealthTech’s $70 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati represented Thorne HealthTech, while Latham & Watkins represented the underwriters in the offering. Thorne HealthTech, a leader in developing innovative solutions...
Codex DNA’s $122 Million IPO
Wilson Sonsini Goodrich & Rosati advised Codex DNA on the deal. Codex DNA, Inc. (Nasdaq: DNAY) announced the closing of its initial public offering of 7,666,664...